Flipping the wound that doesn't heal: the upside of coagulation in cancer.

摘要

With the approval of several antiangio-genic agents including bevacizumab, sunitinb, and sorafenib, the usefulness of targeting tumor vasculature with inhibitors has been clinically established. Antiangiogenic agents may be described as drugs that block angiogenic signaling either by neutralizing secreted proangiogenic factors or by inhibiting intracellular signaling by their receptors resulting in regression of neovasculature in the tumor.